Eli Lilly’s weight-loss pill disappointed in a key trial, but CEO David Ricks and other insiders together bought nearly $3 million worth of stock in the aftermath of the selloff.
Trending
- Fed Officials Are Willing To Cut Rates, But Inflation Could Derail Plans
- The Shutdown Standoff Is Heading for Its Next Big Test
- Russia’s New Jet-Powered Drone Is Immune To Electronic Warfare
- Stocks Point Higher After Down Day for Major Indexes; Gold Surges Further Past $4,000
- Bubble or not, AI continues to draw billions in investments
- I Want to Retire, but I Have to Keep Working so My Adult Kids Have Insurance
- Down 56% since the pandemic, could this iconic British name be the FTSE 250’s biggest bargain?
- These are the best October Prime Day tech deals, updated live
